Liddle's syndrome
A rare genetic disorder affecting kidney function
Liddle's syndrome is a rare genetic disorder characterized by hypertension (high blood pressure) and hypokalemia (low blood potassium levels) due to a defect in the renal tubules of the kidney. It is an autosomal dominant condition, meaning that only one copy of the mutated gene is necessary for the disorder to be expressed.
Pathophysiology

Liddle's syndrome is caused by mutations in the genes encoding the epithelial sodium channel (ENaC) subunits, which are located on the chromosome 16p12. These mutations lead to increased activity of the sodium channels in the collecting ducts of the kidney, resulting in excessive reabsorption of sodium and water, and increased excretion of potassium. This sodium retention leads to volume expansion and hypertension.
Clinical Features
Patients with Liddle's syndrome typically present with early-onset hypertension, often in childhood or early adulthood. The hypertension is often severe and resistant to standard antihypertensive treatments. Hypokalemia is another common feature, which can lead to muscle weakness, fatigue, and cardiac arrhythmias.
Diagnosis
The diagnosis of Liddle's syndrome is based on clinical features, family history, and laboratory findings. Genetic testing can confirm the presence of mutations in the ENaC genes. Laboratory tests typically show low plasma renin activity and low aldosterone levels, despite the presence of hypertension.
Treatment
The treatment of Liddle's syndrome involves the use of potassium-sparing diuretics such as amiloride or triamterene, which directly inhibit the ENaC channels, thereby reducing sodium reabsorption and correcting the hypokalemia. Standard antihypertensive medications are often ineffective.
Prognosis
With appropriate treatment, individuals with Liddle's syndrome can manage their blood pressure and potassium levels effectively, reducing the risk of complications such as stroke and heart disease.
Related pages
Ad. Transform your health with W8MD Weight Loss, Sleep & MedSpa

Tired of being overweight?
Special offer:
Budget GLP-1 weight loss medications
- Semaglutide starting from $29.99/week and up with insurance for visit of $59.99 and up per week self pay.
- Tirzepatide starting from $45.00/week and up (dose dependent) or $69.99/week and up self pay
✔ Same-week appointments, evenings & weekends
Learn more:
- GLP-1 weight loss clinic NYC
- W8MD's NYC medical weight loss
- W8MD Philadelphia GLP-1 shots
- Philadelphia GLP-1 injections
- Affordable GLP-1 shots NYC
|
WikiMD Medical Encyclopedia |
Medical Disclaimer: WikiMD is for informational purposes only and is not a substitute for professional medical advice. Content may be inaccurate or outdated and should not be used for diagnosis or treatment. Always consult your healthcare provider for medical decisions. Verify information with trusted sources such as CDC.gov and NIH.gov. By using this site, you agree that WikiMD is not liable for any outcomes related to its content. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian